Table 3. Associations between genotypes of rs11292 and pCR after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
| Model | Genotype | pCR | Non-pCR | OR (95% CI)ψ | P value |
|---|---|---|---|---|---|
| Codominant | TT | 29 (27.6) | 76 (72.4) | 1.00 | |
| TC | 10 (43.5) | 13 (56.5) | 4.46 (1.26–15.78) | 0.020* | |
| CC | 0 (0.0) | 2 (100.0) | NA | NA | |
| Dominant | TT | 29 (27.6) | 76 (72.4) | 1.00 | |
| TC + CC | 10 (40.0) | 15 (60.0) | 3.41 (1.02–11.33) | 0.046* | |
| Recessive | TT + TC | 39 (30.5) | 89 (69.5) | 1.00 | |
| CC | 0 (0.0) | 2 (100.0) | NA | NA | |
| Overdominant | TT + CC | 29 (27.1) | 78 (72.9) | 1.00 | |
| TC | 10 (43.5) | 13 (56.5) | 4.63 (1.31–16.33) | 0.017* |
ψ, OR and 95% CI was analysed by logistic regression and adjusted by age, menstrual status, and ER, PR and HER2 status. The common genotype was used as a reference; *, P<0.05. pCR, pathological complete response; OR, odds ratios; CI, confidence intervals; NA, not available; ER, estrogen receptor; PR, progesterone receptor; HER2, epidermal growth factor receptor 2.